Recently, an interesting research about blood pressure has been released in the New England Journal of Medicine.
This large, randomized, clinical trial or the SPRINT trial was performed to determine the most appropriate target for systolic blood pressure to reduce cardiovascular morbidity and mortality in patients without diabetes.
The trial was stopped before the initial plan because a systolic blood pressure of <120 mmHg, as compared with less than 140 mmHg, was associated with significantly lower rates of cardiovascular events and death from any cause.
Although we have to pay attention to side effects related to intensive blood-pressure control, such as hypotension or acute renal injury, the results of the SPRINT trial may affect the guidelines of blood-pressure control among selected patients.
You can access the full text at this link.